article thumbnail

Medicare Part D Claims Have Increased, But 340B Prescriptions Increased Faster

Pharmacy Times

The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2013 to 19.3% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% to 49.9%.

article thumbnail

The rise of prescription drug abuse and drug diversion

pharmaphorum

As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Drug diversion is the channelling of prescription drugs from a medical source into the illegal market. The post The rise of prescription drug abuse and drug diversion appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The current pricing of cancer treatments is unsustainable

World of DTC Marketing

One-quarter of all cancer patients chose not to fill a prescription due to cost, according to a 2013 study in The Oncologist. According to a study published in the American Journal of Medicine, more than 42 percent of the 9.5 million people diagnosed with cancer from 2000 to 2012 drained their life’s assets within two years.

article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities. Congress rightly chose to negioate drug prices for Medicare, but prescription drugs are only 10-12% of every healthcare dollar we spend.

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Wall Street wants growth, as do investors, but that may be impossible for pharmaceutical companies. Biogen’s failure should be a warning to other pharma companies.

Pharma 210
article thumbnail

AbbVie CEO looks like a fool before Congress

World of DTC Marketing

The cost of Humira, which is injected via syringe, was more than $72,000 a year on prescription drug websites this week and is not expected to come down until at least 2023. billion on R&D from 2013 to 2018. The increase followed total Humira price hikes of 19 percent during 2017 and 2018. Why the increase? Porter (D-Calif.)

Pharma 181
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf. 1435 (“Affordable Prescriptions for Patients Act of 2021”), [link] gov/bill/117th-congress/senate-bill/1435/text; H.R. Actavis, 570 U.S.